Most cited papers from ImmunoGen (United States)

ImmunoGen (United States)

What are the most cited papers from ImmunoGen (United States)?

The most cited paper from ImmunoGen (United States) is "p53 Has a Direct Apoptogenic Role at the Mitochondria" (Motohiro Mihara, Susan H. Erster, Alexander I. Zaika et al., 2003), with 1,779 citations. Next come "Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate" (1,695) and "Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy" (927).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 61 papers. Every paper with more than 127 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	p53 Has a Direct Apoptogenic Role at the Mitochondria Motohiro Mihara, Susan H. Erster, Alexander I. Zaika et al. · Molecular Cell Open access	Mar 2003	1,779
2	Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate Gail D. Lewis Phillips, Guangmin Li, Debra L. Dugger et al. · Cancer Research	14 Nov 2008	1,695
3	Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy Ravi V. J. Chari, Michael Laurence Miller, Wayne C. Widdison · Angewandte Chemie International Edition	20 Feb 2014	927
4	Puma is an essential mediator of p53-dependent and -independent apoptotic pathways John R. Jeffers, Evan Parganas, Youngsoo Lee et al. · Cancer Cell Open access	Oct 2003	884
5	Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs Ravi V. J. Chari · Accounts of Chemical Research	18 Aug 2007	816
6	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia Zhaohui Gu et al. · Nature Genetics Open access	7 Jan 2019	631
7	RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis Eva González‐Suárez, Allison P. Jacob, Jon C. Jones et al. · Nature	29 Sep 2010	607
8	Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing Hans K. Erickson, Peter U. Park, Wayne C. Widdison et al. · Cancer Research Open access	15 Apr 2006	584
9	Antibody-Drug Conjugates Designed to Eradicate Tumors with Homogeneous and Heterogeneous Expression of the Target Antigen Yelena Kovtun, Charlene A. Audette, Yumei Ye et al. · Cancer Research Open access	15 Mar 2006	480
10	Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer Kathleen N. Moore et al. · New England Journal of Medicine Open access	6 Dec 2023	478
11	Antibody-Drug Conjugate-Based Therapeutics: State of the Science Michael J. Birrer, Kathleen N. Moore, Ilaria Betella et al. · JNCI Journal of the National Cancer Institute	8 Mar 2019	443
12	Antibody Conjugate Therapeutics: Challenges and Potential Beverly A. Teicher, Ravi V. J. Chari · Clinical Cancer Research	14 Oct 2011	426
13	A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation Anna Skaletskaya, Laura M. Bartle, Thomas D. Chittenden et al. · Proceedings of the National Academy of Sciences Open access	26 Jun 2001	421
14	The genomic landscape of pediatric acute lymphoblastic leukemia Samuel W. Brady et al. · Nature Genetics Open access	Sep 2022	416
15	Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study Ursula A. Matulonis, Domenica Lorusso, Ana Oaknin et al. · Journal of Clinical Oncology Open access	30 Jan 2023	393
16	Structural characterization of the maytansinoid–monoclonal antibody immunoconjugate, huN901–DM1, by mass spectrometry Lintao Wang, Godfrey W. Amphlett, Walter A. Blättler et al. · Protein Science Open access	4 Aug 2005	369
17	Gene expression during ER stress–induced apoptosis in neurons Claus Reimertz, Donat Kögel, Abdelhaq Rami et al. · The Journal of Cell Biology Open access	11 Aug 2003	367
18	SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies Jutta Deckert, Marie-Cécile Wetzel, Laura M. Bartle et al. · Clinical Cancer Research	2 Jul 2014	334
19	Antibody–Drug Conjugates for Cancer Treatment John M. Lambert, Anna Berkenblit · Annual Review of Medicine ReviewOpen access	29 Jan 2018	313
20	Semisynthetic Maytansine Analogues for the Targeted Treatment of Cancer Wayne C. Widdison, Sharon D. Wilhelm, Emily E. Cavanagh et al. · Journal of Medicinal Chemistry	10 Jun 2006	313
21	An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Erin K. Maloney, Jennifer L McLaughlin, Nancy E Dagdigian et al. · PubMed	15 Aug 2003	309
22	Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I Kathleen N. Moore, Amit M. Oza, Nicoletta Colombo et al. · Annals of Oncology Open access	2 Mar 2021	304
23	Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review John M. Lambert, Charles Q. Morris · Advances in Therapy Open access	30 Mar 2017	304
24	Effects of Drug–Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody–Maytansinoid Conjugates Xiuxia Sun et al. · Bioconjugate Chemistry	7 Apr 2017	274
25	Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance Yelena Kovtun, Charlene A. Audette, MICHELE F. MAYO et al. · Cancer Research	2 Mar 2010	268
26	Children’s Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia Kimberly P. Dunsmore et al. · Journal of Clinical Oncology Open access	19 Aug 2020	266
27	Immunoconjugates containing novel maytansinoids: promising anticancer drugs. R. V. J. CHARI, B. Martell, Janet L. Gross et al. · PubMed	1992	266
28	New developments for antibody-drug conjugate-based therapeutic approaches Bart ECG de Goeij, John M. Lambert · Current Opinion in Immunology ReviewOpen access	7 Mar 2016	259
29	Cell killing by antibody–drug conjugates Yelena Kovtun, Victor S. Goldmacher · Cancer Letters	6 Jun 2007	243
30	Tumor Delivery and In Vivo Processing of Disulfide-Linked and Thioether-Linked Antibody−Maytansinoid Conjugates Hans K. Erickson, Wayne C. Widdison, MICHELE F. MAYO et al. · Bioconjugate Chemistry	5 Nov 2009	243
31	Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy Ravi V. J. Chari · Advanced Drug Delivery Reviews Review	Apr 1998	235
32	IMGN853, a Folate Receptor-α (FRα)–Targeting Antibody–Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors Olga Ab, Kathleen R. Whiteman, Laura M. Bartle et al. · Molecular Cancer Therapeutics	22 Apr 2015	235
33	Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to Microtubules Manu Lopus, Emin Oroudjev, Leslie Wilson et al. · Molecular Cancer Therapeutics Open access	Oct 2010	234
34	Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study Kathleen N. Moore, Lainie P. Martin, David M. O’Malley et al. · Journal of Clinical Oncology Open access	23 Feb 2017	225
35	Disulfide-Linked Antibody−Maytansinoid Conjugates: Optimization of In Vivo Activity by Varying the Steric Hindrance at Carbon Atoms Adjacent to the Disulfide Linkage Brenda A. Kellogg, Lisa M. Garrett, Yelena Kovtun et al. · Bioconjugate Chemistry	22 Mar 2011	220
36	Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex Diane C. Chugani, Leonard H. Rome, Nancy Kedersha · Journal of Cell Science	Sep 1993	219
37	In vivo depletion of CD4 + FOXP3 + Treg cells by the PC61 anti‐CD25 monoclonal antibody is mediated by FcγRIII + phagocytes Yulius Y. Setiady, Jennifer A. Coccia, Peter U. Park · European Journal of Immunology	28 Dec 2009	217
38	Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid Conjugates Robert Yongxin Zhao, Sharon D. Wilhelm, Charlene A. Audette et al. · Journal of Medicinal Chemistry	25 Apr 2011	215
39	Drug-conjugated monoclonal antibodies for the treatment of cancer John Shearer Lambert · Current Opinion in Pharmacology	9 Aug 2005	210
40	The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo Hiroshi Ikeda et al. · Clinical Cancer Research Open access	15 Jun 2009	204
41	Humanization of murine monoclonal antibodies through variable domain resurfacing. Michael Roguska, Jim Thuesen Pedersen, C Keddy et al. · Proceedings of the National Academy of Sciences Open access	Feb 1994	202
42	Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. C. Liu, B. Mitra Tadayoni, Lizabeth A. Bourret et al. · Proceedings of the National Academy of Sciences Open access	6 Aug 1996	197
43	A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells Yelena Kovtun, Gregory E. Jones, Sharlene Adams et al. · Blood Advances Open access	16 Apr 2018	182
44	SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies Véronique Blanc, Anne Bousseau, Anne Caron et al. · Clinical Cancer Research	14 Oct 2011	169
45	Maytansinoid-Antibody Conjugates Induce Mitotic Arrest by Suppressing Microtubule Dynamic Instability Emin Oroudjev, Manu Lopus, Leslie Wilson et al. · Molecular Cancer Therapeutics Open access	Oct 2010	164
46	Analysis of the composition of immunoconjugates using size‐exclusion chromatography coupled to mass spectrometry Alexandru C. Lazar, Lintao Wang, Walter A. Blättler et al. · Rapid Communications in Mass Spectrometry	8 Jun 2005	156
47	Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma David T. Teachey et al. · Journal of Clinical Oncology Open access	10 Mar 2022	154
48	In Vitroandin VivoActivity of the Maytansinoid Immunoconjugate huN901-N2′-Deacetyl-N2′-(3-Mercapto-1-Oxopropyl)-Maytansine against CD56+ Multiple Myeloma Cells Pierfrancesco Tassone, Antonella Gozzini, Victor S. Goldmacher et al. · Cancer Research	Jul 2004	152
49	RACK1 Is an Insulin-like Growth Factor 1 (IGF-1) Receptor-interacting Protein That Can Regulate IGF-1-mediated Akt Activation and Protection from Cell Death Patrick A. Kiely, Anagha Sant, Rosemary O’Connor · Journal of Biological Chemistry Open access	Jun 2002	152
50	Pharmacokinetics and Biodistribution of the Antitumor Immunoconjugate, Cantuzumab Mertansine (huC242-DM1), and Its Two Components in Mice Hongsheng Xie, Charlene A. Audette, Mary Hoffee et al. · Journal of Pharmacology and Experimental Therapeutics	25 Feb 2004	146

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.